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Abstract 
Aims: To determine the extent of DNA methylation of parvalbumin gene (PVALB) promoter in 
major depressive disorder (MDD) patients with and without suicide attempt in comparison with 
healthy controls.  
Methods: The extracted DNA from dried blood spots of MDD patients (n = 92) including 
non-suicidal MDD and suicidal-MDD subgroups (n = 45 and n = 47, respectively) and age-matched 
control subjects (n = 95) was used for DNA methylation analysis at four CpG sites in the promoter 
sequence of PVALB by pyrosequencing.  
Results: The PVALB methylation was significantly increased at CpG2 and decreased at CpG4 in the 
MDD group compared to the control group, while there was no difference between non-suicidal 
MDD and suicidal-MDD subgroups. A significant inverse correlation of severity of MDD was 
indicated only for CpG4.  
Conclusion: This study provides the first evidence of abnormalities of PVALB promoter 
methylation in MDD and its correlation with MDD severity indicating a role for epigenetics in this 
psychiatric disorder. 
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Introduction 
Major depressive disorder (MDD) is a severe 
neuropsychiatric disorder which is a common public 
health issue for people worldwide. The World Health 
Organization (WHO) has reported that 300 million 
people worldwide suffer from MDD [1]. Around 
800,000 people die from suicide every year [1]. Several 
studies have reported that psychiatric disorders, 
especially MDD, have been strongly linked to suicide 
[2-6]. Moreover, patients with MDD have an almost 
20-fold greater prevalence of suicide attempt than 
other patients hospitalized with no history of MDD 
[7]. 
Recently, the etiology of MDD and suicide 
remains unclear. Nevertheless, there is strong 
evidence for neurobiological deficits in the 
pathophysiology in MDD and suicide. Abnormalities 
of major neurotransmitter systems (serotonin, 
catecholamine, γ-aminobutyric acid (GABA) and 
glutamate) have been widely reported in both MDD 
patients [8,9] and suicidal subjects [10,11]. Epigenetic 
mechanisms, which can be modified by 
environmental factors, may play an important role in 
MDD pathology by genetic alterations in response to 
susceptibility or development to diseases [12-14]. 
DNA methylation is the most widely studied 
epigenetic factor, for which the main mechanism is an 
addition of a methyl group at the cytosine 5’ position 








sites [14,15]. DNA methylation occurring in or near 
promoter regions influences, and generally represses, 
gene transcription. Therefore, DNA methylation is a 
key mechanism that may contribute to the changes in 
gene expression seen in psychiatric disorders. Chen et 
al. have recently reviewed the evidence for the 
involvement of DNA methylation in depression, 
demonstrating particularly how brain-derived 
neurotrophic factor (BDNF) and solute carrier family 
6 member 4 (SLC6A4) genes are implicated and that 
changes in methylation in several other genes 
emerging from whole-genome methylation studies 
have been reported [13]. 
GABA is the most important and abundant 
inhibitory neurotransmitter in the central nervous 
system. Recently, psychiatric disorders have been 
linked with abnormalities of GABAergic 
neurotransmission in schizophrenia, bipolar disorder 
and MDD. In MDD, there have been multiple reports 
of altered GABA content in plasma, cerebrospinal 
fluid (CSF) and brains of depressed patients as well as 
changes in GABA-related gene and protein expression 
[9,16-18]. Moreover, altered mRNA GABAA receptor 
subunit expression was found in postmortem frontal 
cortex in depressed suicide victims [19]. Postmortem 
microarray studies in a cohort of suicides reported 
that GABA-related gene expression was altered in 
suicides both with and without depression in 
prefrontal cortex [20], limbic system [21] and also 
global brain [22]. Moreover, an association of 
depression with GABA-related genes indicated by 
differences in gene expression between suicides with 
and without depression has been reported [20-22]. 
These findings indicate that GABAergic 
neurotransmission is likely to be dysregulated in 
depression and suicide. 
GABAergic interneurons can be subdivided into 
three types based on the expression of the 
calcium-binding proteins calbindin, calretinin and 
parvalbumin (PV) [23]. Specific deficits of 
PV-immunoreactive cells are found in the brain in 
both schizophrenia and its animal models, and 
recently an increase of PV gene (PVALB) promoter 
methylation has been recently reported in 
hippocampal tissue from both schizophrenia [24] and 
its sub-chronic phencyclidine rat model [25]. Further 
evidence implicating PVALB promoter 
hypermethylation in psychosis comes from the study 
of methamphetamine-induced psychosis subjects [26]. 
While frontal cortical PV protein or PVALB expression 
are not reportedly changed in MDD [27-29], deficits of 
PVALB expression in anterior cingulate cortex have 
been observed [30]. Thus, as there are reported 
changes in genes and proteins related to GABAergic 
neurotransmission in MDD, the present study 
hypothesized that DNA methylation of PVALB may 
be abnormal in this disorder. This study examined 
DNA methylation within the promoter sequence of 
PVALB in MDD patients both with and without a 
history of attempted suicide. Exploration of the 
relationship between DNA methylation in the PVALB 
promoter with symptom severity of MDD was a 
secondary objective of this study. 
Materials and methods 
Subjects 
The subject groups collected for this study 
comprised 100 unmedicated MDD patients and 100 
age- and sex-matched control subjects (18-65 years 
old). MDD patients were diagnosed by a researcher 
psychiatrist in Clinical Psychiatry, Maharaj Nakorn 
Chiang Mai Hospital, Thailand based on criteria in the 
Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition (DSM-5). Exclusion criteria for 
patients included a previous history of schizophrenia, 
bipolar disorder, or drug abuse. The subjects in the 
MDD group were divided into two subgroups of 
non-suicidal MDD and suicidal-MDD groups based 
on their suicide attempt history determined by the 
psychiatrist according to the Mini International 
Neuropsychiatric Interview (M.I.N.I.) (Thai version 
5.0.0 - Revised 2007). The 17 Item Hamilton 
Depression Rating Scale Thai version (HAMD-7) was 
used for assessing severity of depression. The control 
subjects completed the Thai Mental Health Indicator 
(TMHI-66) for evaluation of mental health. Volunteers 
with previous history of schizophrenia, mood 
disorder, anxiety, or drug addiction and abnormal 
mental health were excluded from this study. 
The experimental procedures of this study were 
approved by the Naresuan University Institutional 
Review Board, Thailand and the Research Ethics 
Committee, Faculty of Medicine, Chiang Mai 
University, Thailand. Informed consent forms were 
obtained from the participants involved. 
Blood sample collection and DNA extraction 
Fingertip blood samples were collected on 
Whatman FTA™ cards (GE Healthcare) using Chelex® 
100 resin (Bio-Rad) following a modified protocol 
from application note 28-9822-22 AA by GE 
Healthcare (GE Healthcare). Then FTA discs were 
punched from dried blood spots using a Harris Micro 
Punch 2.0 mm (GE Healthcare, USA) and used for 
DNA extraction. Briefly, FTA discs were washed three 
times in 1 ml high-purity water by incubation at room 
temperature for 10 min with occasional inverting, 
centrifugation at 20,000 x g for 3 min and discarding 
the water in each time. Subsequently, 5% Chelex® 100 
resin (Bio-Rad) was added and incubated at 56°C for 




20 min. The samples were mixed by vortexing, further 
incubated at 100°C for 8 min and then centrifuged at 
20,000 x g for 3 min. The supernatant containing 
genomic DNA was carefully collected and the 
concentration determined using NanoDrop® ND-1000 
(Thermo Fisher Scientific). 
Bisulfite conversion and methylation analysis 
Bisulfite conversion of 500 ng genomic DNA 
template for each reaction was performed using 
EpiTect® Fast DNA Bisulfite Conversion kit 
(QIAGEN) according to the manufacturer’s protocol.  
The extent of DNA methylation within a 
promoter sequence of PVALB (Homo sapiens 
chromosome 22, GRCh38.p12 Primary Assembly, 
NCBI Reference Sequence: NC_000022.11 (36800701. 
.36819473, complement)) (Figure 1) and long 
interspersed nucleotide element-1 (LINE-1) genes was 
evaluated using the pyrosequencing technique 
according to the protocol recommended by the 
manufacturer (QIAGEN). The present study used a 
set of primers: forward primer: 5’-AGTGGAGA 
GAGAAAGGGAGTA-3’, biotinylated reverse primer: 
5’-AACACCAAAAAAAAAACCACCTCTAAAAT-3’ 
and sequencing primer: 5’-ATTAGTTAAGGTTTT 
TAGATTTGA-3’ (Eurofins MWG Operon) [24,26] to 
quantify methylation of four CpG sites of PVALB. In 
addition, predesigned PyroMark® CpG LINE-1 Assay 
(QIAGEN) containing proprietary forward, 
biotinylated reverse and sequencing primers to detect 
three CpG sites located at positions 331 to 318 of 
LINE-1 (GenBank accession number X58075) was 
used. 
The PCR reaction included 1x PyroMark PCR 
Master Mix, 1x CoralLoad Concentrate (only for the 
reaction of PVALB), 0.2 µM of forward and reverse 
primers, RNase-free water and 1 ng bisulfite- 
converted DNA template in 25 µl PCR final volume. 
The PCR amplification was conducted with initial 
PCR activation step at 95°C for 15 min, 45 cycles of 
denaturation at 94°C for 30 s, annealing at 56°C (for 
PVALB) / 50°C (for LINE-1) for 30 s and extension at 
72°C for 30 s, and final extension step at 72°C for 10 
min. A quality of PCR product was checked by 
agarose gel analysis with ethidium staining prior to 
Pyrosequencing analysis (Figure 2A-2B). Then, ten 
microliter of PCR product was immobilized with 
Streptavidin SepharoseTM High Performance (GE 
Healthcare) and purified using the PyroMark Q24 
Vacuum workstation following the manufacturer’s 
instructions (QIAGEN). The samples then underwent 
pyrosequencing to determine methylation using the 
PyroMark Q24 system according to the instructions 
from the manufacturer (QIAGEN). The percentage 
methylation at each CpG site in a pyrogram was 
calculated by Pyromark® Q24 2.0.6.20 software 
(QIAGEN). All results which were labelled as “check” 
or “failed” were repeated from the PCR amplification 
step. All samples that failed to provide reliable results 
after replication were rejected. 
Statistical analysis 
The Statistical Package for the Social Sciences 
(SPSS) software version 17.0 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis. A 
difference in sex distribution was tested using 
Chi-square tests. Comparisons of differences in age, 
duration of illness, HAMD-17 score and percentage of 
DNA methylation were analyzed using non- 
parametric Mann-Whitney test or Kruskal-Wallis test. 
Correlation was evaluated using Spearman’s rank 
correlation. The significance level was set at p < 0.05. 
GraphPad Prism® version 8.0 for Windows (La Jolla, 
CA, USA) was used to create scatter dot plots. 
 
 
Figure 1. Illustration of the CpG sites and primers used for DNA methylation analysis of PVALB promotor region on chromosome 22. The target region consists of 217 bp 
containing four CpG sites. 
 





Figure 2. Illustration of the PCR product bands of (A) PVALB (217 bp) and (B) LINE-1 (146 bp) on agarose gel visualized under ultraviolet (UV) illumination. Lane 1: 100 bp DNA 
ladder. Lane 2-8: Control sample 1-7. Lane 9-15: MDD sample 1-7. 
 
Figure 3. Comparison of DNA methylation (%) of the four consecutive CpG sites in PVALB promoter between control and MDD groups. Scatter dot plots of each groups are 
horizontally lined with the median value. * p < 0.05. MDD: Major depressive disorder. 
 
Results 
All samples showed single PCR bands without 
evidence of DNA degradation before determination of 
PVALB and LINE-1 methylations (Figure 2). Eight 
MDD and five control samples were rejected on the 
basis of unreliable pyrosequencing results for either 
PVALB or LINE-1, leaving an MDD group of 68 
females and 24 males (43.13 ± 14.72 years old) and a 
control group of 71 females and 24 males (43.06 ± 
15.03 years old) with complete data. DNA 
methylation status of the four CpG sites in the PVALB 
promoter sequence of MDD and control groups is 
shown in Figure 3. While the mean percentage 
methylation at the four CpG sites showed no 
significant effect in MDD group (Z = -0.762; p = 0.446), 
a significant increase in percentage methylation at 
CpG2 (Z = -2.021; p = 0.043) and a significant decrease 
in percentage methylation at CpG4 (Z = -2.161; p = 
0.031) were seen. The methylation at each of these two 
CpG sites was not significantly different when 
comparing non-suicidal MDD and suicidal-MDD 
groups (Z = -0.144; p = 0.885 and Z = -1.172; p = 0.241, 
respectively) (Figure 4), nor between these MDD 
subgroups and control group (ꭓ2 = 4.090; df = 2; p = 
0.129 and ꭓ2 = 5.571; df = 2; p = 0.062, respectively). 
Mean LINE-1 methylation showed no significant 
difference between MDD and control groups (70.85 ± 
1.63 vs 70.95 ± 1.68; Z = -0.389; p = 0.697), nor between 
non-suicidal MDD and suicidal-MDD groups (70.77 ± 
1.33 vs 70.93 ± 1.89; Z = -0.894; p = 0.371). Methylation 
of CpG2, but no other PVALB sites, was significantly 
negatively correlated with LINE-1 methylation in the 
control group (r = -0.230, p = 0.025), but not in the 
MDD group (r = -0.184, p = 0.079). 





Table 1. Demographic data and clinical characteristics of control and MDD groups, and non-suicidal MDD and suicidal-MDD subgroups. 
 Control  
(n = 95) 
(mean ± SD) 
MDD 
(n = 92) 
(mean ± SD) 
p-value Non-suicidal MDD  
(n = 45) 
(mean ± SD) 
Suicidal-MDD 
(n = 47) 
(mean ± SD) 
p-value 
Age (years) 43.06 ± 15.03 43.13 ± 14.72 0.928 42.62 ± 15.15 43.62 ± 14.45 0.860 
Sex (n, female/male) 71/24 68/24 0.897 35/10 33/14 0.409 
Duration of illness (years)    5.30 ± 5.75 10.15 ± 10.25 0.011* 
HAMD-17 (scores)    11.69 ± 7.43 13.47 ± 7.38 0.225 
Data are represented as mean ± SD or number (n). 
* p < 0.05. 
HAMD: Hamilton depression rating scale; MDD: Major depressive disorder. 
 
 
Figure 4. Comparison of DNA methylation (%) of the four consecutive CpG sites in PVALB promoter between non-suicidal MDD and suicidal-MDD groups. Scatter dot plots 
of each groups are horizontally lined with the median value. MDD: Major depressive disorder. 
 
Figure 5. The correlation of PVALB methylation at CpG4 and HAMD-17 scores among MDD patients. HAMD: Hamilton depression rating scale. 
 
The demographic and clinical variables are 
shown in Table 1. A significant correlation between 
age and LINE-1 methylation was observed in both 
control and MDD groups (r = -0.331; p = 0.001 and r = 
0.328; p = 0.001, respectively) with no difference in age 
neither between control and MDD groups nor 
between non-suicidal MDD and suicidal-MDD 
subgroups (data not shown). The duration of illness in 
the non-suicidal MDD group was significantly lower 
than the suicidal-MDD group (Z = -2.534; p = 0.011). 




Moreover, a significant correlation of methylation 
with duration of illness was found for LINE-1 (r = 
0.266; p = 0.010), but not for any PVALB site (data not 
shown). Although no significant difference of 
HAMD-17 score was observed between non-suicidal 
MDD and suicidal-MDD groups (Z = -1.212; p = 
0.225), a highly significant correlation with HAMD-17 
score was apparent for CpG4 methylation (r = -0.287; 
p = 0.005), but not for CpG2 (r = -0.024; p = 0.820) 
(Figure 5). This effect remained after controlling for 
age and sex in a partial Pearson correlation analysis (p 
= 0.016). 
Discussion 
The main finding in this study was the 
site-specific change in PVALB promoter methylation 
which was increased at CpG2 and decreased at CpG4 
in Thai MDD patients. This occurred along with no 
change of global DNA methylation represented by 
LINE-1 methylation. Moreover, we found a strong 
association of PVALB promoter methylation at CpG4 
with the severity of depression, but no association 
with suicide attempt in MDD patients. 
The present study has assessed DNA 
methylation at the same CpG sites of the PVALB 
promoter as previous studies in humans [24,26], and 
(for CpG2) the equivalent sequence in rats [25]. 
Interestingly, the finding of elevated DNA 
methylation at CpG2 was also previously observed 
associated with schizophrenia [24] and 
methamphetamine dependence, especially 
methamphetamine-induced psychosis [26], in 
humans, and at the equivalent site in brain tissue from 
rats receiving phencyclidine [25]. While the previous 
consistent findings indicate that hypermethylation of 
PVALB at CpG2 might be generally associated with 
psychotic illness and animal model of schizophrenia, 
these results suggest that this epigenetic change may 
extend to other psychiatric disorders, in this case 
MDD. 
The decrease in methylation at CpG4 associated 
with MDD is in contrast to the increase at this site in 
post-mortem hippocampus in schizophrenia subjects 
[24], while no significant difference was identified in 
methamphetamine-induced psychosis subjects [26]. 
The validity of this finding is supported by the highly 
significant inverse correlation of CpG4 methylation 
with the severity of depression indicated by 
HAMD-17 scores, an independent effect of age or sex. 
Reanalysis of the data excluding outlying subjects 
gave essentially the same result (data not shown).  
In the mammalian genome, most CpG sites are 
normally methylated while CpG residues enriched in 
CpG islands, particularly located in or near gene 
promoter regions, are relatively protected from 
methylation. An elevation of DNA methylation or 
hypermethylation at such CpG islands often results in 
blocking transcriptional initiation leading to 
repression of gene expression [31], while a reduction 
of DNA methylation or hypomethylation may lead to 
increased gene expression [32].  
However, the direct relationship between DNA 
methylation and gene expression of PVALB is 
unknown, although the findings described above in 
schizophrenia and its animal model show both 
increased methylation and reduced expression of 
PVALB. In contrast, previous studies in postmortem 
brain in MDD have demonstrated no changes of 
PVALB gene expression or neuronal 
immunoreactivity in most brain regions studied 
[27-29,33], other than the anterior cingulate [30]. These 
findings imply that the PVALB methylation profiles 
might influence the pathology of MDD in specific 
brain regions. To support this hypothesis, 
hypermethylation of the PVALB promoter has been 
identified specifically in only hippocampus, but not 
prefrontal cortex, in schizophrenia [24].  
LINE-1 methylation provides an indication of 
global DNA methylation levels. This study has found 
that the LINE-1 methylation was positively correlated 
with age, but not associated with MDD. A positive 
relationship between LINE-1 methylation and age is 
well established and has also been reported in 
psychiatric disorders [34]. However, unchanged 
LINE-1 methylation from this study is in agreement 
with a previous finding in blood samples in MDD 
[35]. The lack of any indication of a change in global 
DNA methylation indicates that the findings in 
PVALB are independent of such an effect and perhaps 
specific for that gene. 
One important but inevitable limitation of this 
study is that the PVALB promoter methylation was 
determined in DNA derived from peripheral blood 
samples. While studies in post-mortem tissue from 
psychiatric patients have been undertaken [24], DNA 
methylation is most often investigated in blood 
samples, while there is evidence from previous 
studies of concordant changes in methylation between 
blood and brain [36]. We have also observed increased 
PVALB methylation in blood samples similar to 
reported changes in brain tissue in schizophrenia 
(Reynolds et al., unpublished data). There have been 
other findings of DNA methylation from blood 
samples of patients with MDD. Changes in 
methylation profiles of specific genes such as zinc 
finger and BTB domain containing 20 (ZBTBT20) [37], 
BDNF [38-42] and nuclear receptor subfamily 3, group 
C, member 1 (NR3C1) [43] have been reported. We do 
not know the direction of causality in these findings, 
i.e. whether the changes in PVALB methylation are a 




contributor to, or a consequence of, MDD and, for 
CpG4, depressive symptom severity. While some of 
these findings may also be confounded by drug 
treatment, we can exclude this influence this influence 
in the current study using unmedicated subjects. 
In summary, this study provides the first 
evidence of changes in the PVALB promoter 
methylation in MDD. PVALB promoter methylation 
was increased at CpG2 and decreased at CpG4 in 
MDD patients, effects that were independent of a 
measure of global DNA methylation. Moreover, the 
decrease in PVALB methylation at CpG4 correlated 
strongly with severity of depression. Further studies 
need to determine how these findings might reflect 
changes in PVALB methylation within the brain and 
their impact on gene expression and, eventually, 
GABAergic neuronal function. 
Acknowledgments 
We are very grateful to all subjects for 
participation, the staff of Clinical Psychiatry, Maharaj 
Nakorn Chiang Mai Hospital, Thailand and the 
graduate students of Department of Anatomy, Faculty 
of Medical Science, Naresuan University, Thailand, 
for data and blood collections as well as Biomolecular 
Sciences Research Centre, Sheffield Hallam 
University, UK for facility support. This work was 
financially supported by the Naresuan University 
Research Fund and the funding from commission 
higher education by Naresuan University, and 
partially supported by Chiang Mai University. B 
Thaweethee-Sukjai was financially supported the 
Thailand Research Fund through the Royal Golden 
Jubilee Ph.D Program (Grant No. PHD/0297/2552) 
and the British Council through the Newton Fund: 
PhD Placement grant for scholars 2015/16. 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1.  [Internet] World Health Organization: Geneva, Switzerland. Depression. 
Revised 22 March 2018. 
https://www.who.int/en/news-room/fact-sheets/detail/depression.  
2.  Rich CL, Young D, Fowler RC. San Diego suicide study. I. Young vs old 
subjects. Arch. Gen. Psychiatry. 1986; 43: 577-82. 
3.  Henriksson MM, Aro HM, Marttunen MJ, et al. Mental disorders and 
comorbidity in suicide. Am. J. Psychiatry. 1993; 150: 935-40. 
4.  Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED. 
Relationships of age and axis I diagnoses in victims of completed suicide: a 
psychological autopsy study. Am. J. Psychiatry. 1996; 153: 1001-8. 
5.  Harwood D, Hawton K, Hope T, Jacoby R. Psychiatric disorder and 
personality factors associated with suicide in older people: a descriptive and 
case-control study. Int. J. Geriatr. Psychiatry. 2001; 16: 155-65. 
6.  Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 
suicides: a meta-analysis. BMC psychiatry. 2004; 4: 1-37. 
7.  Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in 
mental disorders: a meta-review. World Psychiatry. 2014; 13:153–60. 
8.  Gao SF, Bao AM. Corticotropin-releasing hormone, glutamate, and 
gamma-aminobutyric acid in depression. Neuroscientist. 2011; 17: 124-44. 
9.  Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major 
depressive disorder. Mol. Psychiatry. 2010; 16: 383-406. 
10.  Sudol K, Mann JJ. Biomarkers of suicide attempt behavior: Towards a 
biological model of risk. Curr. Psychiatry Rep. 2017; 19: 31. 
11.  Oquendo MA, Sullivan GM, Sudol K, et al. Toward a biosignature for sicide. 
Am. J. Psychiatry. 2014; 171:1259-77. 
12.  Saavedra K, Molina-Marquez AM, Saavedra N, Zambrano T, Salazar LA. 
Epigenetic modifications of major depressive disorder. Int. J. Mol. Sci. 2016; 17: 
pii: E1279. 
13.  Chen D, Meng L, Pei F, Zheng Y, Leng J. A review of DNA methylation in 
depression. J. Clin. Neurosci. 2017; 43 (Supplement C): 39-46. 
14.  Portela A, Esteller M. Epigenetic modifications and human disease. Nat. 
Biotechnol. 2010; 28: 1057-68. 
15.  Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J. 
Cell. Physiol. 2007; 213: 384-90. 
16.  Hasler G. Pathophysiology of depression: do we have any solid evidence. 
World Psychiatry. 2010; 9: 155-61. 
17.  Croarkin PE, Levinson AJ, Daskalakis ZJ. Evidence for GABAergic inhibitory 
deficits in major depressive disorder. Neurosci. Biobehav. Rev. 2011; 35: 
818-25. 
18.  Pehrson AL, Sanchez C. Altered γ-aminobutyric acid neurotransmission in 
major depressive disorder: a critical review of the supporting evidence and the 
influence of serotonergic antidepressants. Drug Des. Devel. Ther. 2015; 9: 
603-24. 
19.  Merali Z, Du L, Hrdina P, et al. Dysregulation in the suicide brain: mRNA 
expression of corticotropin-releasing hormone receptors and GABA(A) 
receptor subunits in frontal cortical brain region. J. Neurosci. 2004; 24: 1478-85. 
20.  Klempan TA, Sequeira A, Canetti L, et al. Altered expression of genes 
involved in ATP biosynthesis and GABAergic neurotransmission in the 
ventral prefrontal cortex of suicides with and without major depression. Mol. 
Psychiatry. 2009; 14: 175-89. 
21.  Sequeira A, Klempan T, Canetti L, et al. Patterns of gene expression in the 
limbic system of suicides with and without major depression. Mol. Psychiatry. 
2007; 12: 640-55. 
22.  Sequeira A, Mamdani F, Ernst C, et al. Global brain gene expression analysis 
Links glutamatergic and GABAergic alterations to suicide and major 
depression. PloS one. 2009; 4: e6585. 
23.  Lund JS, Lewis DA. Local circuit neurons of developing and mature macaque 
prefrontal cortex: Golgi and immunocytochemical characteristics. J. Comp. 
Neurol. 1993; 328: 282-312. 
24.  Fachim HA, Srisawat U, Dalton CF, Reynolds GP. Parvalbumin promoter 
hypermethylation in postmortem brain in schizophrenia. Epigenomics. 2018; 
10: 519-24. 
25.  Fachim HA, Srisawat U, Dalton CF, et al. Subchronic administration of 
phencyclidine produces hypermethylation in the parvalbumin gene promoter 
in rat brain. Epigenomics. 2016; 8: 1179-83. 
26.  Veerasakul S, Watiktinkorn P, Thanoi S, et al. Increased DNA methylation in 
the parvalbumin gene promoter is associated with methamphetamine 
dependence. Pharmacogenomics. 2017; 18: 1317-22. 
27.  Sibille E, Morris HM, Kota RS, Lewis DA. GABA-related transcripts in the 
dorsolateral prefrontal cortex in mood disorders. Int. J. 
Neuropsychopharmacol. 2011; 14: 721-34. 
28.  Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal 
cortical GABAergic neurons in schizophrenia defined by the presence of 
calcium-binding proteins. Biol. Psychiatry. 2002; 52: 708-15. 
29.  Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. 
GABAergic neurons immunoreactive for calcium binding proteins are 
reduced in the prefrontal cortex in major depression. 
Neuropsychopharmacology. 2007; 32: 471-82. 
30.  Tripp A, Oh H, Guilloux JP, Martinowich K, Lewis DA, Sibille E. 
Brain-derived neurotrophic factor signaling and subgenual anterior cingulate 
cortex dysfunction in major depressive disorder. Am. J. Psychiatry. 2012; 169: 
1194-202. 
31.  Moore LD, Le T, Fan G. DNA methylation and its basic function. 
Neuropsychopharmacology. 2013; 38: 23-38. 
32.  Wagner JR, Busche S, Ge B, Kwan T, Pastinen T, Blanchette M. The 
relationship between DNA methylation, genetic and expression 
inter-individual variation in untransformed human fibroblasts. Genome Biol. 
2014; 15: R37. 
33.  Zhang ZJ, Reynolds GP. A selective decrease in the relative density of 
parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. 
Schizophr. Res. 2002; 55: 1-10. 
34.  Li S, Yang Q, Hou Y, et al. Hypomethylation of LINE-1 elements in 
schizophrenia and bipolar disorder. J. Psychiatr. Res. 2018; 107: 68-72. 
35.  Nantharat M, Wanitchanon T, Amesbutr M, Tammachote R, Praphanphoj V. 
Glucocorticoid receptor gene (NR3C1) promoter is hypermethylated in Thai 
females with major depressive disorder. Genet. Mol. Res. 2015; 14: 19071-79. 
36.  Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA 
methylation associated with Parkinson disease: identification of concordant 
epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 
2013; 8: 1030-38. 
37.  Davies MN, Krause L, Bell JT, et al. Hypermethylation in the ZBTB20 gene is 
associated with major depressive disorder. Genome Biol. 2014; 15: R56. 




38.  Januar V, Ancelin ML, Ritchie K, Saffery R, Ryan J. BDNF promoter 
methylation and genetic variation in late-life depression. Transl. Psychiatry. 
2015; 5: e619. 
39.  Fuchikami M, Morinobu S, Segawa M, et al. DNA methylation profiles of the 
brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic 
biomarker in major depression. PloS one. 2011; 6: e23881. 
40.  D'Addario C, Dell'Osso B, Galimberti D, et al. Epigenetic modulation of BDNF 
gene in patients with major depressive disorder. Biol. Psychiatry. 2013; 73: 
e6-7. 
41.  Dell'Osso B, D'Addario C, Carlotta Palazzo M, et al. Epigenetic modulation of 
BDNF gene: differences in DNA methylation between unipolar and bipolar 
patients. J. Affect. Disord. 2014; 166: 330-33. 
42.  Kang HJ, Kim JM, Lee JY, et al. BDNF promoter methylation and suicidal 
behavior in depressive patients. J. Affect. Disord. 2013; 151: 679-85. 
43.  Na K-S, Chang HS, Won E, et al. Association between glucocorticoid receptor 
methylation and hippocampal subfields in major depressive disorder. PloS 
one. 2014; 9: e85425. 
